NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
06/14/2022
Back to search
Official data from USPTO
TYVASO DPI (TREPROSTINIL) INHALATION POWDER
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
26
Latest update
06/14/2022
Trademark type
Combined
Nice classes
5
Filing date
12/09/2020
Registration date
06/14/2022
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
06/14/2022
Last transaction
06/14/2022
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
10/28/2020
First use in commerce
10/28/2020
Drawing code
3
Owner type
03
Owner location
Silver Spring, MD, US
Examiner
CROWLEY, SEAN
Law office
M70
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the words "TYVASO/DPI" above the wording "(treprostinil) INHALATION POWDER" with two arcs to the right of the wording.
Holders and representatives
Holders
U. C. (pessoa física)
Representatives
Norm J. Rich FOLEY & LARDNER LLP
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension and interstitial lung diseaseidiopathic pulmonary fibrosiswhere the pharmaceutical preparations contain prostaglandins
Publications
History of USPTO decisions and trademark events.
26 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
06/14/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/29/2022
PUBO
PUBLISHED FOR OPPOSITION
03/29/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
03/09/2022
AAUA
NOTICE OF ACCEPTANCE OF AMENDMENT TO ALLEGE USE E-MAILED
02/18/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
02/17/2022
IUAA
USE AMENDMENT ACCEPTED
02/17/2022
XAEC
EXAMINER'S AMENDMENT ENTERED
02/16/2022
ALIE
ASSIGNED TO LIE
02/16/2022
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
02/15/2022
GNEA
EXAMINERS AMENDMENT E-MAILED
02/15/2022
CNEA
EXAMINERS AMENDMENT -WRITTEN
02/15/2022
AUPC
AMENDMENT TO USE PROCESSING COMPLETE
11/30/2021
IUAF
USE AMENDMENT FILED
11/30/2021
EAAU
TEAS AMENDMENT OF USE RECEIVED
11/29/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
11/18/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
11/18/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
11/18/2021
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
06/10/2021
GNRT
NON-FINAL ACTION E-MAILED
06/10/2021
CNRT
NON-FINAL ACTION WRITTEN
06/10/2021
DOCK
ASSIGNED TO EXAMINER
05/28/2021
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
02/17/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
02/16/2021
NWAP
NEW APPLICATION ENTERED
12/12/2020
Continuous trademark protection
Get notified about every new filing that threatens TYVASO DPI (TREPROSTINIL) INHALATION POWDER or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.